Onco Actu du 4 novembre 2016

	2. Etiologie
Seven substances added to 14th Report on Carcinogens [NIH] Five viruses, a chemical, and a metallic element listed in new HHS report.
Seven agents, including HIV, added to U.S. list of carcinogens [Reuters] The inclusion of these seven new agents brings the cumulative total up to 248 listings. A listing indicates a cancer hazard, but does not by itself imply the substance or virus will cause cancer, the HHS said.
	2.9 Etiologie - Tabac
Scientists reveal genetic ‘signatures’ left by cigarette smoke [Cancer Research UK] Strikingly, it seems that different tissues of the body display different hallmarks of smoking damage, underlining once again just how devastating smoking can be.
DNA study lays bare devastating damage caused by smoking [The Guardian] People who smoke a pack of cigarettes each day for a year develop on average 150 extra mutations in every lung cell, and nearly 100 more mutations than usual in each cell of the voice box, researchers found. More still build up in the mouth, bladder, liver and other organs.
Smoking a pack a day causes 150 mutations in every lung cell, research shows [Reuters] This study analyzed over 5,000 tumors, comparing cancers from smokers with those from people who had never smoked.
	3.1 Tabac
Exclusive - Tobacco treaty leaders propose barring delegates linked to state firms [Reuters] The proposal, if adopted at the conference of the Framework Convention on Tobacco Control (FCTC) in India, could restrict delegations sent by countries like China and Vietnam, where governments own cigarette companies and have in the past sent representatives linked to the industry.
	3.2 Prévention - Obésité
Childhood obesity levels hit ‘devastating record high’ [Cancer Research UK] “The trend over the last decade is showing no signs of slowing down, and this worrying news is something that could have been prevented with more government action."
Child obesity rising again, NHS report reveals [The Guardian] The figures come after Theresa May’s government was criticised for watering down the childhood obesity strategy that her predecessor, David Cameron, intended to publish.
	5. Traitements
Ribociclib for HR-Positive Breast Cancer [Now@NEJM] The duration of progression-free survival was longer in all preplanned patient subgroups receiving ribociclib, including those with newly diagnosed or pretreated metastatic disease and those with or without liver or lung metastases.
Missile tracking [The Economist] Many anti-cancer drugs bind readily to metal ions, including those of copper, manganese and zirconium. That interested Dr de Rosales and Dr Gabizon, because these three elements all have radioactive isotopes that release a particle called a positron as part of their decay.
	5.10 Traitements - Essais
What clinical trial results? Now you can see who isn’t sharing their findings [STAT] “If any institution is concerned that it is doing badly in our tables, then there is one simple thing they can do: publish their trial results, using their trial registry number, so that this information can be accessed and read by doctors, researchers and patients.”
Sanofi, Novartis, NCI, Ranbaxy top missing data list as Shire most transparent [FierceBiotech] Sanofi: failed to report on 65.5% of the trials it sponsored--285 trials missing out of 435. Hôpitaux de Paris: failed to report on 63.7%% of the trials it sponsored--186 trials missing out of 292 NCI: failed to report on 34.8% of the trials it sponsored--194 trials missing out of 558
Tracker flags up failures to report clinical trials [Nature] Goldacre and his Oxford-based co-author Anna Powell-Smith developed the tool to search the ClinicalTrials.gov database for trials that were completed at least two years ago. The computer then attempted to match those trials with results published in that database or in the research repository PubMed.
The TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions [F1000 Research] We have designed, built, and launched an easily accessible online service, the TrialsTracker, that identifies sponsors who have failed in their duty to make results of clinical trials available, and which can be maintained at low cost. Sponsors who wish to improve their performance metrics in this tool can do so by publishing the results of their trials.
	5.12.2 Immunothérapies - CAR-T
Celyad chief blasts Cellectis’ CEO Choulika, claiming he lied about CAR-T patent [EndPoints] Celyad says Cellectis CEO André Choulika claimed at a shareholders meeting a few days ago that claim 1 to their Patent N° 9,181,527 was invalidated by the US patent office, which they say is “false and misleading.” But Cellectis isn’t backing away quietly from this fight.
	5.2.1 Pharma - Partenariats
Stand Up To Cancer Announces SU2C Catalyst™ Collaboration with Genentech to Support New Research on Cancer Treatments and Therapies [AACR] Genentech will provide funding to support several research projects of $1 to $3 million each over a three-year grant term. Applications will be evaluated by a subcommittee of the SU2C Catalyst Executive Committee.
	5.2.3 Pharma - économie
Boehringer backs $20M round in ADC cancer player [FierceBiotech] Basel, Switzerland-based NBE is currently wrapping up lead optimization and characterization work on its two lead programs, the targets of which remain a secret. One of the ADCs is aimed at multiple myeloma; the other is being looked at in leukemia, triple-negative breast cancer and lung cancer.
	5.4 Traitements - Economie
Blood cancer sufferers to receive early access to BMS' Opdivo [Pharmafile] Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through the Early Access to Medicines Scheme (EAMS) by the Medicines Healthcare Products and Regulatory Agency (MHRA). The drug will be made available to patients suffering from relapsed or refractory classical Hodgkin lymphoma (cHL) as a monotherapy after autologous stem cell transplant and treatment with brentuximab vedotin.
	5.8 ASH
Shaky early results on novel drugs send biotech stocks crashing [STAT] Trillium’s early data is particularly disappointing, because there’s been an upsurge in interest in the target it’s been chasing — a protein called CD47 that Stanford researchers have found proliferating on the surface of tumor cells.
The losers are piling up after today’s big ASH abstract drop [EndPoints] Today is the big drop for ASH abstracts, and Spark isn’t the only biotech company to be damaged in the response to some of the safety warnings or weak results to hit the biotech circuit on Twitter.
	5.8.1 ASH - Communiqués
Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016 [Juno] New data with JCAR017 in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which is a subtype of NHL, and final data from the PLAT-02 trial for pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL) will be presented.
ASH 2016: Janssen to Present 43 Abstracts with Data on Ibrutinib, Daratumumab and Other Compounds Showing Treatment Advances in Malignant and Non-Malignant Hematologic Conditions [Janssen] Key data include Phase 2 five-year follow-up data for ibrutinib in CLL and updated Phase 3 depth of response data for daratumumab in combination with standard of care therapies for patients with multiple myeloma who have received at least one prior therapy
Seattle Genetics Announces ASH 2016 Abstracts Highlighting Company’s Expanding Global Leadership in the Development of Innovative Antibody-Drug Conjugates [Seattle Genetics] Oral Presentation on Phase 3 ALCANZA Trial in CD30-Expressing Cutaneous T-Cell Lymphoma.
ImmunoGen Announces Preclinical Data Presentations for Two ADCs With Novel IGN Payloads at Upcoming 58th ASH Annual Meeting [ImmunoGen] In an oral presentation, the Company will report preclinical data demonstrating the activity of IMGN632 in multiple acute myeloid leukemia (AML) models and patient samples at concentrations far below levels that affect normal bone marrow cells, suggesting the potential for efficacy in AML patients in the absence of or with limited myelosuppression.
Bristol-Myers Squibb to Present New Data at the 58th Annual Meeting & Exposition of the American Society of Hematology Demonstrating Research Advancements in Immuno-Oncology and Across Multiple Blood Cancers [BMS] First disclosure of preliminary results from Phase 1/2 study of Opdivo in combination with ADCETRIS (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma.
AbbVie to Showcase Growing Oncology Portfolio and Commitment to Treating Blood Cancers at the 2016 American Society of Hematology Annual Meeting [AbbVie] - Results to be presented from ibrutinib clinical studies across multiple blood cancers - New data to be presented investigating venetoclax as monotherapy and in combination for the treatment of several blood cancers
Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 Pivotal Trial in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL) at the 2016 American Society Hematology Annual Meeting [Kite] Oral Presentation of Clinical Data from First Fully Human Anti-CD19 Chimeric Antigen Receptor (huCAR-19) Investigational Cell Therapy to Enter Clinical Study.
Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting [Takeda] Demonstrating Expertise and Leadership in Hematologic Oncology, Presentations Include Phase 3 Data on ADCETRIS® (brentuximab vedotin) in CD30-Positive Cutaneous T-Cell Lymphoma, NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma and Emerging Pipeline.
Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting [Roche] New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session.
	6. Lutte contre les cancers
We need better treatments for childhood cancer, with fewer side effects [The Conversation] The Australian government today announced A$20 million for research to find targeted treatments for childhood cancer.
	6.11 Patients
Living With Cancer: A Shortage of Oncologists [NY Times] Women with ovarian cancer are told repeatedly that we must find a specialist. Yet in many areas of the country, it is impossible.
	6.6 Publications
Hey scientists, how much of your publication success is due to dumb luck? [Science] Randomness appears to play the predominant role in determining which of a scientist’s papers get cited the most, concludes a study out today in Science.
Authors retract third cancer paper for missing original data [Retraction Watch] We’ve previously reported on two retractions of papers co-authored by Bhagavathi Narayanan and Narayanan K. Narayanan, previously based at the New York University (NYU) School of Medicine.
	6.7 DMP, Big Data & applis
Will Big Data Cure Cancer? [Fortune] When the government launched the Cancer Genome Atlas, it spent $100 million to get data from 50,000 people. Of that, data from 24,000 people was unusable, he said.
Flatiron, Foundation Med Link Records of 20,000 Cancer Patients [Xconomy] Each company has what the other one lacks. Flatiron, based in New York, is in the medical records business and says it has signed up more than 250 cancer clinics around the country. It is privately held, has 350 employees, and has raised more than $300 million in venture capital. Cambridge, MA-based Foundation has a tumor sequencing business.